<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937322</url>
  </required_header>
  <id_info>
    <org_study_id>003.GID.2016.D</org_study_id>
    <nct_id>NCT04937322</nct_id>
  </id_info>
  <brief_title>Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry.</brief_title>
  <official_title>Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bile duct cancer and pancreatic cancer are cancers that cannot be surgically removed. As the&#xD;
      cancer grows, it blocks the drainage of the bile ducts that carry digestive juices from the&#xD;
      gallbladder and pancreas to the small intestine. ERCP (endoscopic retrograde&#xD;
      cholangiopancreatography) is often prescribed during which a tube with a tiny camera attached&#xD;
      is inserted through the subject's mouth and advanced to a place in the small intestine where&#xD;
      the bile duct empties. Through this scope the doctor enlarges the ducts with tiny balloons&#xD;
      and places plastic or metal stents (straws) that help keep the bile ducts open so they can&#xD;
      drain properly. However, due to the cancer, the stents are blocked eventually.&#xD;
&#xD;
      The purpose of this registry is to record information and evaluate the impact of endoscopic&#xD;
      radiofrequency ablation (RFA) probes in improving the management of bile duct cancer or&#xD;
      pancreatic cancer by ablating the tissue in the bile duct(s) before the stent(s) are&#xD;
      implanted. By using radiofrequency (RF) energy to heat the tissue in the duct(s) prior to&#xD;
      stent(s) insertion, the surrounding tissue becomes coagulated and this may delay tumor growth&#xD;
      and the time before the stent lumen becomes blocked. Thereby, allowing increased periods&#xD;
      between the need for intervention and further stent implantation(s). The registry will&#xD;
      evaluate the efficacy and safety of RFA procedures conducted for pancreatico-biliary&#xD;
      disorders&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Bile duct cancer and pancreatic cancer are cancers that cannot be surgically removed. As the&#xD;
      cancer grows, it blocks the drainage of the bile ducts that carry digestive juices from the&#xD;
      gallbladder and pancreas to the small intestine. ERCP (endoscopic retrograde&#xD;
      cholangiopancreatography) is often prescribed during which a tube with a tiny camera attached&#xD;
      is inserted through the subject's mouth and advanced to a place in the small intestine where&#xD;
      the bile duct empties. Through this scope the doctor enlarges the ducts with tiny balloons&#xD;
      and places plastic or metal stents (straws) that help keep the bile ducts open so they can&#xD;
      drain properly. However, due to the cancer, the stents are blocked eventually.&#xD;
&#xD;
      The purpose of this registry is to record information and evaluate the impact of endoscopic&#xD;
      radiofrequency ablation (RFA) probes in improving the management of bile duct cancer or&#xD;
      pancreatic cancer by ablating the tissue in the bile duct(s) before the stent(s) are&#xD;
      implanted. By using radiofrequency (RF) energy to heat the tissue in the duct(s) prior to&#xD;
      stent(s) insertion, the surrounding tissue becomes coagulated and this may delay tumor growth&#xD;
      and the time before the stent lumen becomes blocked. Thereby, allowing increased periods&#xD;
      between the need for intervention and further stent implantation(s). The registry will&#xD;
      evaluate the efficacy and safety of RFA procedures conducted for pancreatico-biliary&#xD;
      disorders&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The safety and efficacy of various radio frequency ablation probes have been assessed in a&#xD;
      series of studies. This multi-center registry has been initiated since June 2011 and is&#xD;
      ongoing until June 2017:&#xD;
&#xD;
        -  To document the immediate and post procedure clinical performance of radio frequency&#xD;
           ablation in a &quot;real world&quot; patient population requiring stent implantation for&#xD;
           pancreatico-biliary disorders.&#xD;
&#xD;
        -  To assess the immediate and 6 months post procedure adverse event rate in patients.&#xD;
&#xD;
        -  To assess the impact of RFA on the life expectancy of patients suffering from&#xD;
           pancreatico-biliary malignancies.&#xD;
&#xD;
      Study Design at Coordinating Center - Weill Cornell Medical College Primary site (WCMC):&#xD;
&#xD;
      This study entails review of data from a database protocol [IRB # 1104011642 : collected for&#xD;
      non-research related purposes]. The purpose of this protocol is to establish a database that&#xD;
      captures all Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and&#xD;
      Interventional endoscopy cases. Its objective is to assess prospectively the efficacy and&#xD;
      safety of these routine procedures to permit identification of technical details about the&#xD;
      procedures or other factors, which might be associated with outcome or results. Assessment of&#xD;
      these details would help us with problem identification and recommendations to improve health&#xD;
      outcomes and quality of life in these patients&#xD;
&#xD;
      The registry will review and document:&#xD;
&#xD;
        -  All patients who have had Interventional Endoscopy procedures done which involved radio&#xD;
           frequency ablations for pancreatico-biliary disorders since June 2011 and extending&#xD;
           forward through June 2017.&#xD;
&#xD;
        -  Data will be reviewed and collected from database protocol IRB # 1104011642.&#xD;
&#xD;
        -  No subject intervention is involved in this study. Subject contact is not needed for&#xD;
           database review.&#xD;
&#xD;
      Study Design at Secondary sites:&#xD;
&#xD;
      The registry will review and document:&#xD;
&#xD;
        -  All patients who have had Interventional Endoscopy procedures done which involved radio&#xD;
           frequency ablations for pancreatico-biliary disorders.&#xD;
&#xD;
        -  No subject intervention is involved in this study. Subject contact is not needed for&#xD;
           retrospective review.&#xD;
&#xD;
        -  These sites would have IRB approved protocols to collect and send radio frequency&#xD;
           ablation procedure data to the primary site (WCMC). Additionally, the secondary study&#xD;
           sites would mention WCMC as an entity that could receive PHI in their prospective&#xD;
           protocols and consent/HIPAA forms.&#xD;
&#xD;
        -  All secondary study sites' IRB approvals will be sent to the primary/coordinating study&#xD;
           center at WCMC. The primary center will then forward these IRB approvals to WCMC IRB as&#xD;
           soon as they are received from the secondary study sites.&#xD;
&#xD;
        -  Relevant IRB documentation will be maintained at both primary and secondary sites.&#xD;
&#xD;
      Registry Hosting:&#xD;
&#xD;
      The coordinating center and primary site (WCMC) will host the registry on the local servers.&#xD;
&#xD;
      A secure Data management or Electronic Data Capture (EDC) system will be used for data entry,&#xD;
      compilation and querying.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Measurement of Bile Duct Stricture Diameter</measure>
    <time_frame>June 2011 through June 2021</time_frame>
    <description>Change from Baseline in Bile Duct Stricture Diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>June 2011 through June 2021</time_frame>
    <description>Number of Participants with Adverse Events, Type of adverse events, frequency and intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival duration</measure>
    <time_frame>June 2011 through June 2023</time_frame>
    <description>Documentation of response rates and overall survival duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent occlusion-free duration</measure>
    <time_frame>June 2011 through June 2023</time_frame>
    <description>Documentation of overall stent occlusion-free duration</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Bile Duct Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Interventional Endoscopy procedures</arm_group_label>
    <description>All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations for pancreatico-biliary disorders since June 2011 and extending forward through June 2023.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interventional Endoscopy procedures</intervention_name>
    <description>â€¢ All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.</description>
    <arm_group_label>Interventional Endoscopy procedures</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have had Interventional Endoscopy procedures done which involved radio&#xD;
        frequency ablations and stent insertion(s) for pancreatico-biliary disorders.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who have had Interventional Endoscopy procedures done which involved&#xD;
             radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.&#xD;
&#xD;
          -  Above 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who has not undergone interventional endoscopy with RFA and stent&#xD;
             insertion(s).&#xD;
&#xD;
          -  Below 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prashant Kedia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Dallas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP, endoscopic retrograde cholangiopancreatography</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>pancreatico-biliary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be collected and entered at/submitted to the primary site (WCMC).&#xD;
A secure Access Database or an alternative secure Electronic Data Capture (EDC) system hosted on the WCMC server will be used for data entry, compilation and reporting.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>June 2011 through June 2023</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

